Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | No Grouping
Number of items: 7.

Journal Article

Kunzmann, Volker, Siveke, Jens T., Alguel, Hana, Goekkurt, Eray, Siegler, Gabriele, Martens, Uwe, Waldschmidt, Dirk, Pelzer, Uwe ORCID: 0000-0001-9213-2737, Fuchs, Martin, Kullmann, Frank, Boeck, Stefan, Ettrich, Thomas J., Held, Swantje, Keller, Ralph, Klein, Ingo, Germer, Christoph-Thomas, Stein, Hubert, Friess, Helmut, Bahra, Marcus, Jakobs, Ralf, Hartlapp, Ingo and Heinemann, Volker (2021). Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol. Hepatol., 6 (2). S. 128 - 139. SAN DIEGO: ELSEVIER INC. ISSN 2468-1253

Hartlapp, Ingo, Alguel, Hana, Goekkurt, Eray, Siegler, Gabriele, Martens, Uwe, Waldschmidt, Dirk, Pelzer, Uwe ORCID: 0000-0001-9213-2737, Hennes, Elke, Fuchs, Martin, Siveke, Jens, Kullmann, Frank, Boeck, Stefan, Ettrich, Thomas J., Ferenczy, Peter, Keller, Ralph, Germer, Christoph-Thomas, Stein, Hubert, Klein, Ingo ORCID: 0000-0003-1097-0986, Heinemann, Volker and Kunzmann, Volker (2020). Induction Chemotherapy in Locally Advanced Pancreatic Cancer (LAPC) - Final Results of a Multicenter Randomized Phase 2 AIO Trial (NEOLAP). Oncol. Res. Treat., 43. S. 63 - 64. BASEL: KARGER. ISSN 2296-5262

Sinn, Marianne, Sinn, Bruno, V, Treue, Denise, Keilholz, Ulrich, Damm, Frederik, Schmuck, Rosa, Lohneis, Philipp, Klauschen, Frederick, Striefler, Jana K., Bahra, Marcus, Blaeker, Hendrik, Bischoff, Sven, Pelzer, Uwe ORCID: 0000-0001-9213-2737, Oettle, Helmut, Riess, Hanno, Budczies, Jan and Denkert, Carsten (2020). TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial. Clin. Cancer Res., 26 (14). S. 3732 - 3740. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1557-3265

Kunzmann, Volker, Martens, Uwe Marc, Alguel, Hana, Siveke, Jens T., Goekkurt, Eray, Pelzer, Uwe ORCID: 0000-0001-9213-2737, Siegler, Gabriele Margareta, Hennes, Elke, Waldschmidt, Dirk, Jakobs, Ralf, Ferenczy, Peter, Keller, Ralph, Boeck, Stefan Hubert, Kullmann, Frank, Kapp, Markus and Germer, Christoph Thomas (2018). Secondary resectability in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- versus FOLFIRINOX-based induction chemotherapy: Interim results of a randomized phase II AIO trial (NEOLAP). J. Clin. Oncol., 36 (4). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Waidmann, Oliver, Pelzer, Uwe ORCID: 0000-0001-9213-2737, Boeck, Stefan and Waldschmidt, Dirk-Thomas (2018). Sequence therapy in metastatic pancreatic cancer. Z. Gastroent., 56 (6). S. 578 - 583. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1439-7803

Lohneis, Philipp, Sinn, Marianne, Klein, Fritz, Bischoff, Sven, Striefler, Jana K., Wislocka, Lilianna, Sinn, Bruno V., Pelzer, Uwe ORCID: 0000-0001-9213-2737, Oettle, Helmut, Riess, Hanno, Denkert, Carsten, Blaeker, Hendrik and Juehling, Anja (2018). Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma. Br. J. Cancer, 118 (11). S. 1485 - 1492. LONDON: NATURE PUBLISHING GROUP. ISSN 1532-1827

Sinn, Marianne, Bahra, Marcus, Liersch, Torsten, Gellert, Klaus, Messmann, Helmut, Bechstein, Wolf ORCID: 0000-0002-3267-8145, Waldschmidt, Dirk, Jacobasch, Lutz, Wilhelm, Martin, Rau, Bettina M., Gruetzmann, Robert, Weinmann, Arndt ORCID: 0000-0003-1198-1716, Maschmeyer, Georg, Pelzer, Uwe ORCID: 0000-0001-9213-2737, Stieler, Jens M., Striefler, Jana K., Ghadimi, Michael, Bischoff, Sven, Doerken, Bernd, Oettle, Helmut and Riess, Hanno (2017). CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial. J. Clin. Oncol., 35 (29). S. 3330 - 3341. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

This list was generated on Sun Oct 13 12:12:04 2024 CEST.